Table 3. Top 15 dark HNSCC mutation-enriched pathways.
| Pathway | Number of Mutated Genes | Proportion Pathway Mutated | Proportion of HNSCC cohort with ≥1 mutated gene in pathway | Number of patients with ≥1 mutated gene in pathway |
|---|---|---|---|---|
| Collagen biosynthesis and modifying enzymes | 64 | 1 | 0.52071006 | 264 |
| Laminin interactions | 23 | 1 | 0.32741617 | 166 |
| NICD traffics to nucleus | 13 | 1 | 0.25641026 | 130 |
| Notch-HLH transcription pathway | 13 | 1 | 0.25641026 | 130 |
| Receptor-ligand binding initiates the second proteolytic cleavage of Notch receptor | 14 | 1 | 0.23865878 | 121 |
| Platelet calcium homeostasis | 19 | 1 | 0.21301775 | 108 |
| Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling | 5 | 1 | 0.17751479 | 90 |
| Adenylate cyclase activating pathway | 10 | 1 | 0.17554241 | 89 |
| Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | 7 | 1 | 0.17357002 | 88 |
| Vitamin D (calciferol) metabolism | 7 | 1 | 0.16370809 | 83 |
| Dermatan sulfate biosynthesis | 11 | 1 | 0.13609467 | 69 |
| GABA A receptor activation | 13 | 1 | 0.13412229 | 68 |
| regulation of FZD by ubiquitination | 21 | 1 | 0.13412229 | 68 |
| Reduction of cytosolic Ca++ levels | 10 | 1 | 0.12820513 | 65 |
| CHL1 interactions | 9 | 1 | 0.12426036 | 63 |
Dark pathways ranked first according to proportion of pathway mutated and second according to proportion of cohort with mutated gene.